VRXAW — Veraxa Biotech AG - Post de-SPAC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079109 ·
Switzerland
Last close
$0.06
Market Cap
—
52W High
$0.07
52W Low
$0.06
ADV30
127,195
Next earnings
—
No quarterly fundamentals indexed for this ticker.
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.03T | $1157.08 | — |
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
News headlines (Yahoo Finance, 1h cache)
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
2026-09-04 11:00 · Yahoo
VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
2026-08-28 19:00 · Yahoo
VERAXA Biotech (VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
2026-08-24 18:00 · Yahoo
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
2026-08-24 11:00 · Yahoo
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
2026-08-06 18:30 · Yahoo
VERAXA Biotech (VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
2026-07-30 18:15 · Yahoo
VERAXA Biotech (VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
2026-07-29 19:30 · Yahoo
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
2026-07-29 11:00 · Yahoo
VERAXA Biotech (VRXA) Shareholders Approve Corporate Governance, Financing Measures
2026-07-28 17:45 · Yahoo
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
2026-07-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.